niacinamide has been researched along with Liver Cirrhosis in 96 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection." | 9.16 | Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| "Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles." | 9.14 | Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. ( Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T, 2009) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 8.88 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. ( Spechler, SJ; Wang, DH; Xie, B, 2012) |
| "Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function." | 8.87 | Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. ( Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F, 2011) |
| "Because of low accrual, no conclusion can be drawn on the sorafenib PK in patients with advanced HCC and Child-Pugh B liver cirrhosis." | 7.96 | Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ( Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O, 2020) |
| "Use of sorafenib remains debated in elderly patients treated for advanced hepatocellular carcinoma (HCC)." | 7.85 | Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. ( Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N, 2017) |
| "Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC)." | 7.85 | Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. ( Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG, 2017) |
| "Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC)." | 7.83 | Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. ( Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK, 2016) |
| "Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)." | 7.83 | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016) |
| "Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued." | 7.81 | Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma. ( BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H, 2015) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | 7.81 | Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "Recently, the oral multikinase inhibitor sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC)." | 7.80 | Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib. ( Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2014) |
| "To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis." | 7.80 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. ( Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D, 2014) |
| "Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function." | 7.79 | Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013) |
| "This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 7.79 | Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. ( Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W, 2013) |
| " The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy." | 7.78 | Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2012) |
| "Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively." | 7.78 | The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T, 2012) |
| " Several preclinical studies have demonstrated a beneficial effect of the multikinase inhibitor sorafenib on the portal hypertensive syndrome." | 7.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Tolerability and toxicity of a systemic treatment with sorafenib are moderate in patients with liver cirrhosis in Child A or B." | 7.77 | Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. ( Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L, 2011) |
| "An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC)." | 7.76 | Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. ( Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A, 2010) |
| "Sorafenib is the standard treatment for patients with an advanced stage of hepatocellular carcinoma (HCC)." | 7.76 | Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. ( Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP, 2010) |
| "To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib." | 7.75 | UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. ( Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R, 2009) |
| "Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis." | 7.75 | Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. ( Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A, 2009) |
| "Serum and urinary levels (mean +/- SEM) of N-methylnicotinamide and urinary excretion of 2-pyridone-5-carboxamide were measured in 10 healthy controls and 10 patients with liver cirrhosis in basal conditions and after a nicotinamide oral load (1." | 7.71 | The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production. ( Budillon, G; Cuomo, R; Pumpo, R; Sarnelli, G; Spinella, A, 2001) |
| " Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib." | 5.72 | Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. ( Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A, 2022) |
| "The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and the proportion of older patients with HCC is expected to steadily rise in the next years." | 5.39 | Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. ( Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2013) |
| " The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection." | 5.16 | Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| " Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma." | 5.15 | Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. ( Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O, 2011) |
| "Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles." | 5.14 | Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. ( Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T, 2009) |
| "Sorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma." | 4.88 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. ( Spechler, SJ; Wang, DH; Xie, B, 2012) |
| "Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function." | 4.87 | Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. ( Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F, 2011) |
| "Because of low accrual, no conclusion can be drawn on the sorafenib PK in patients with advanced HCC and Child-Pugh B liver cirrhosis." | 3.96 | Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. ( Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O, 2020) |
| "Use of sorafenib remains debated in elderly patients treated for advanced hepatocellular carcinoma (HCC)." | 3.85 | Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. ( Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N, 2017) |
| "Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC)." | 3.85 | Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. ( Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG, 2017) |
| "Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)." | 3.83 | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016) |
| "Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC)." | 3.83 | Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. ( Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK, 2016) |
| "Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued." | 3.81 | Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma. ( BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H, 2015) |
| "Patients with advanced hepatocellular carcinoma (aHCC) and portal vein tumor thrombus (PVTT) still have a very poor prognosis, even though the oral multikinase inhibitor sorafenib has revolutionized treatment of aHCC in patients with liver cirrhosis (LC)." | 3.81 | Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. ( Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N, 2015) |
| "To investigate in greater detail the efficacy and safety of sorafenib for the treatment of hepatocellular carcinoma (HCC) in patients with established cirrhosis." | 3.80 | Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. ( Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D, 2014) |
| "Sorafenib--a broad kinase inhibitor--is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC." | 3.80 | Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. ( Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX, 2014) |
| "Recently, the oral multikinase inhibitor sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC)." | 3.80 | Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib. ( Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2014) |
| "Sorafenib (SO) was the first systemic agent to demonstrate a significant improvement in overall survival in patients with advanced hepatocellular carcinoma (HCC); international guidelines now recommend SO as a first-line treatment in patients with unresectable HCC who are not eligible for locoregional therapies and maintain preserved liver function." | 3.79 | Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit. ( D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P, 2013) |
| "This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment." | 3.79 | Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. ( Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W, 2013) |
| " The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) receiving sorafenib therapy." | 3.78 | Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N, 2012) |
| " Several preclinical studies have demonstrated a beneficial effect of the multikinase inhibitor sorafenib on the portal hypertensive syndrome." | 3.78 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. ( Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W, 2012) |
| "Sorafenib is currently approved for advanced hepatocellular carcinoma (HCC) and is presently being studied as an adjuvant treatment for HCC following resection." | 3.78 | The effects of sorafenib on liver regeneration in a model of partial hepatectomy. ( Espat, NJ; Falanga, V; Katz, SC; Kurniali, PC; O'Gara, K; Somasundar, P; Wang, LJ; Wang, X, 2012) |
| "Patients with advanced hepatocellular carcinoma who were treated with sorafenib at Queen Mary Hospital, Hong Kong, China, were analyzed retrospectively." | 3.78 | The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. ( Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T, 2012) |
| "Tolerability and toxicity of a systemic treatment with sorafenib are moderate in patients with liver cirrhosis in Child A or B." | 3.77 | Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. ( Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L, 2011) |
| "An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC)." | 3.76 | Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. ( Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A, 2010) |
| "Hepatocellular carcinoma (HCC) is increasing in numbers worldwide, and no effective systemic treatment existed for advanced HCC until SHARP (Sorafenib in HCC Assessment Randomized Protocol) study proved sorafenib (Nexavar((R)), Bayer Pharmaceuticals, Wayne, NJ, USA) prolonged survival versus placebo." | 3.76 | Platelet count less than SHARP: what does a case series reveal? ( Saif, MW, 2010) |
| "Sorafenib is the standard treatment for patients with an advanced stage of hepatocellular carcinoma (HCC)." | 3.76 | Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. ( Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP, 2010) |
| "Deletion of glycine N-methyltransferase (GNMT), the main gene involved in liver S-adenosylmethionine (SAM) catabolism, leads to the hepatic accumulation of this molecule and the development of fatty liver and fibrosis in mice." | 3.76 | Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. ( Calvisi, DF; Embade, N; Esteller, M; Fernández-Ramos, D; Frades, I; Fraga, MF; Julve, J; Lu, SC; Luka, Z; Martínez-Chantar, ML; Martínez-López, N; Mato, JM; Rodríguez, J; Rodríguez-Millán, E; Torres, L; Varela-Rey, M; Wagner, C; Woodhoo, A, 2010) |
| "Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis." | 3.75 | Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. ( Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A, 2009) |
| "To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib." | 3.75 | UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. ( Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R, 2009) |
| "Serum and urinary levels (mean +/- SEM) of N-methylnicotinamide and urinary excretion of 2-pyridone-5-carboxamide were measured in 10 healthy controls and 10 patients with liver cirrhosis in basal conditions and after a nicotinamide oral load (1." | 3.71 | The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production. ( Budillon, G; Cuomo, R; Pumpo, R; Sarnelli, G; Spinella, A, 2001) |
| " Less than 10% of patients showed evidence of vitamin B12, nicotinic acid, thiamin, or riboflavin deficiency, and 17% had evidence of folic acid deficiency." | 3.65 | Nutrition in cryptogenic cirrhosis and chronic aggressive hepatitis. ( Kelleher, J; Losowsky, MS; Morgan, AG; Walker, BE, 1976) |
| "Hepatocellular carcinoma is the sixth most prevalent cancer and the third most frequent cause of cancer-related death." | 2.48 | Hepatocellular carcinoma. ( Bruix, J; Forner, A; Llovet, JM, 2012) |
| "It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%." | 2.47 | Adjuvant therapy after curative treatment for hepatocellular carcinoma. ( Kudo, M, 2011) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| " Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib." | 1.72 | Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model. ( Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A, 2022) |
| "We found NR could prevent liver fibrosis and reverse the existing liver fibrosis." | 1.51 | Nicotinamide riboside protects against liver fibrosis induced by CCl ( Huang, Y; Jiang, R; Jiang, X; Li, X; Ling, W; Pang, N; Pei, L; Qiu, Y; Wan, T; Wang, S; Yang, H; Yang, L; Ye, M; Zhang, Z; Zhou, Y, 2019) |
| "At diagnosis Barcelona Clinic Liver Cancer staging (BCLC) was 0 (8%), A (48%), B (20%), C (17%), and D (7%)." | 1.48 | Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. ( Dore, GJ; Gomaa, A; Waked, I; Waziry, R, 2018) |
| "The tyrosine kinase inhibitors sorafenib and imatinib are important in the treatment of a range of cancers but adverse effects in some patients necessitate dosage modifications." | 1.48 | Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. ( Edwards, RJ; Ghassabian, S; Gillani, TB; Murray, M; Rawling, T, 2018) |
| "Liver fibrosis is an important process that occurs in most types of chronic liver diseases and often results in the end stage of liver diseases, such as cirrhosis, portal hypertension, and hepatocellular carcinoma." | 1.48 | Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice. ( Chen, Y; Dong, H; Liu, X; Ma, Z; Wang, L; Xia, D; Xiong, Y, 2018) |
| "However, the association of T2DM with liver cirrhosis and therapy response in HCC patients is not clear." | 1.48 | Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma. ( Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A, 2018) |
| "Sorafenib is a tyrosine kinase inhibitor that has recently been shown to be a potential antifibrotic agent." | 1.43 | Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. ( Chen, Y; Chiang, T; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC; Wan, D; Wang, L, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) has emerged as an important cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC)." | 1.43 | Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. ( Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC, 2016) |
| "Both sorafenib and SC-1 ameliorated liver fibrosis in vivo and promoted HSC apoptosis in vitro." | 1.42 | Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. ( Chen, DS; Chen, KF; Chen, PJ; Cheng, HR; Huang, HP; Jao, P; Jeng, YM; Kao, JH; Liu, CH; Liu, CJ; Shiau, CW; Su, TH; Tai, WT; Tseng, TC; Yang, HC, 2015) |
| "Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group." | 1.42 | Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. ( Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP, 2015) |
| "According to the Barcelona Clinic Liver Cancer staging system, 60." | 1.42 | [Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice]. ( Artaza Varasa, T; de la Cruz Pérez, G; Gómez Rodríguez, R; González de Frutos, C; Muñoz López, D; Romero Gutiérrez, M; Ruano Díaz, L; Sánchez Ruano, JJ, 2015) |
| "The therapeutic effects on liver fibrosis of sorafenib, a multiple tyrosine kinase inhibitor, and gadolinium chloride (GdCl3), which depletes KCs, were evaluated in rats." | 1.42 | Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats. ( Chen, X; Liu, C; Lu, Y; Miao, H; Tang, B; Wang, L; Xu, Q; Yang, Z, 2015) |
| "Sorafenib treatment significantly inhibited LX-2 proliferation by >75% (7." | 1.39 | Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. ( Chou, H; Fiel, MI; Friedman, SL; Hong, F, 2013) |
| "The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and the proportion of older patients with HCC is expected to steadily rise in the next years." | 1.39 | Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. ( Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2013) |
| "In vivo, NA significantly attenuated liver fibrosis in TAA-treated rats as assessed by histological analysis using hematoxylin-eosin and Masson's trichrome staining." | 1.37 | Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells. ( Jang, JJ; Jin, J; Lee, KB; Park, SY, 2011) |
| "Sorafenib is a receptor tyrosine kinase inhibitor that blocks growth factor signaling in tumor cells but also displays important and not yet fully characterized effects on liver nonparenchymal cells including HSCs and LECs." | 1.37 | Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. ( Blechacz, B; Ehman, R; Glaser, K; Huebert, R; Lomberk, G; Masyuk, T; Patel, L; Ritman, E; Routray, C; Shah, V; Shergill, U; Thabut, D; Urrutia, R; Vercnocke, A, 2011) |
| "Sorafenib treatment attenuated liver fibrosis and was associated with a significant decrease in intrahepatic fibrogenesis, hydroxyproline accumulation and collagen deposition." | 1.36 | New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. ( Gao, J; Jiang, H; Ma, J; Wang, Y; Zhang, D; Zhang, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (11.46) | 18.7374 |
| 1990's | 2 (2.08) | 18.2507 |
| 2000's | 11 (11.46) | 29.6817 |
| 2010's | 66 (68.75) | 24.3611 |
| 2020's | 6 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Biliotti, E | 1 |
| Giampaoli, O | 1 |
| Sciubba, F | 1 |
| Marini, F | 1 |
| Tomassini, A | 1 |
| Palazzo, D | 1 |
| Capuani, G | 1 |
| Esvan, R | 1 |
| Spaziante, M | 1 |
| Taliani, G | 1 |
| Miccheli, A | 1 |
| Chapin, WJ | 1 |
| Hwang, WT | 1 |
| Karasic, TB | 1 |
| McCarthy, AM | 1 |
| Kaplan, DE | 1 |
| Kurma, K | 1 |
| Zeybek Kuyucu, A | 1 |
| Roth, GS | 1 |
| Sturm, N | 1 |
| Mercey-Ressejac, M | 1 |
| Abbadessa, G | 1 |
| Yu, Y | 1 |
| Lerat, H | 1 |
| Marche, PN | 1 |
| Decaens, T | 1 |
| Macek Jilkova, Z | 1 |
| Baweja, S | 1 |
| Kumari, A | 1 |
| Negi, P | 1 |
| Tomar, A | 1 |
| Tripathi, DM | 1 |
| Mourya, AK | 1 |
| Rastogi, A | 1 |
| Subudhi, PD | 1 |
| Thangariyal, S | 1 |
| Kumar, G | 1 |
| Kumar, J | 1 |
| Reddy, GS | 1 |
| Sood, AK | 1 |
| Vashistha, C | 1 |
| Sarohi, V | 1 |
| Bihari, C | 1 |
| Maiwall, R | 1 |
| Sarin, SK | 1 |
| Labeur, TA | 1 |
| Achterbergh, R | 1 |
| Takkenberg, B | 1 |
| Van Delden, O | 1 |
| Mathôt, R | 1 |
| Klümpen, HJ | 1 |
| Blanc, JF | 1 |
| Khemissa, F | 1 |
| Bronowicki, JP | 1 |
| Monterymard, C | 1 |
| Perarnau, JM | 1 |
| Bourgeois, V | 1 |
| Obled, S | 1 |
| Abdelghani, MB | 1 |
| Mabile-Archambeaud, I | 1 |
| Faroux, R | 1 |
| Seitz, JF | 1 |
| Locher, C | 1 |
| Senellart, H | 1 |
| Villing, AL | 1 |
| Audemar, F | 1 |
| Costentin, C | 1 |
| Deplanque, G | 1 |
| Manfredi, S | 1 |
| Edeline, J | 1 |
| Williet, N | 1 |
| Clavel, L | 1 |
| Bourmaud, A | 1 |
| Verot, C | 1 |
| Bouarioua, N | 1 |
| Roblin, X | 1 |
| Merle, P | 1 |
| Phelip, JM | 1 |
| Guerrini, GP | 1 |
| Berretta, M | 2 |
| Tarantino, G | 2 |
| Magistri, P | 1 |
| Pecchi, A | 1 |
| Ballarin, R | 2 |
| Di Benedetto, F | 2 |
| Makol, A | 1 |
| Kanthaje, S | 1 |
| Dhiman, RK | 1 |
| Kalra, N | 1 |
| Chawla, YK | 1 |
| Chakraborti, A | 1 |
| Murray, M | 1 |
| Gillani, TB | 1 |
| Ghassabian, S | 1 |
| Edwards, RJ | 1 |
| Rawling, T | 1 |
| Cheng, Y | 1 |
| Zheng, H | 1 |
| Wang, B | 1 |
| Xu, W | 1 |
| Xu, J | 1 |
| Zhu, Y | 1 |
| Waziry, R | 1 |
| Gomaa, A | 1 |
| Waked, I | 1 |
| Dore, GJ | 1 |
| Komatsu, M | 1 |
| Kanda, T | 1 |
| Urai, H | 1 |
| Kurokochi, A | 1 |
| Kitahama, R | 1 |
| Shigaki, S | 1 |
| Ono, T | 1 |
| Yukioka, H | 1 |
| Hasegawa, K | 1 |
| Tokuyama, H | 1 |
| Kawabe, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Ma, Z | 1 |
| Liu, X | 1 |
| Dong, H | 1 |
| Xia, D | 1 |
| Wang, L | 3 |
| Chen, Y | 3 |
| Xiong, Y | 1 |
| Takeuchi, K | 1 |
| Yokouchi, C | 1 |
| Goto, H | 1 |
| Umehara, K | 1 |
| Yamada, H | 1 |
| Ishii, Y | 1 |
| Jiang, R | 1 |
| Zhou, Y | 1 |
| Wang, S | 1 |
| Pang, N | 1 |
| Huang, Y | 3 |
| Ye, M | 1 |
| Wan, T | 1 |
| Qiu, Y | 1 |
| Pei, L | 1 |
| Jiang, X | 1 |
| Yang, H | 1 |
| Ling, W | 1 |
| Li, X | 1 |
| Zhang, Z | 1 |
| Yang, L | 1 |
| Brandi, G | 1 |
| de Rosa, F | 1 |
| Calzà, L | 1 |
| Girolamo, SD | 1 |
| Tufoni, M | 1 |
| Ricci, CS | 1 |
| Cirignotta, F | 1 |
| Caraceni, P | 1 |
| Biasco, G | 1 |
| Vogel, W | 2 |
| D'Angelo, S | 1 |
| Secondulfo, M | 1 |
| De Cristofano, R | 1 |
| Sorrentino, P | 1 |
| Safran, H | 1 |
| Charpentier, KP | 1 |
| Kaubisch, A | 1 |
| Mantripragada, K | 1 |
| Dubel, G | 1 |
| Perez, K | 1 |
| Faricy-Anderson, K | 1 |
| Miner, T | 1 |
| Eng, Y | 1 |
| Victor, J | 1 |
| Plette, A | 1 |
| Espat, J | 1 |
| Bakalarski, P | 1 |
| Wingate, P | 1 |
| Berz, D | 1 |
| Luppe, D | 1 |
| Martel, D | 1 |
| Rosati, K | 1 |
| Aparo, S | 1 |
| Deng, YR | 1 |
| Ma, HD | 1 |
| Tsuneyama, K | 1 |
| Yang, W | 1 |
| Wang, YH | 1 |
| Lu, FT | 1 |
| Liu, CH | 2 |
| Liu, P | 1 |
| He, XS | 1 |
| Diehl, AM | 1 |
| Gershwin, ME | 1 |
| Lian, ZX | 1 |
| Nagai, H | 3 |
| Kanekawa, T | 2 |
| Kobayashi, K | 1 |
| Mukozu, T | 3 |
| Matsui, D | 3 |
| Matsui, T | 2 |
| Kanayama, M | 2 |
| Wakui, N | 3 |
| Momiyama, K | 3 |
| Shinohara, M | 2 |
| Ishii, K | 2 |
| Igarashi, Y | 3 |
| Sumino, Y | 3 |
| Reiberger, T | 2 |
| Duyverman, AM | 1 |
| Huang, P | 1 |
| Samuel, R | 1 |
| Hiddingh, L | 1 |
| Roberge, S | 1 |
| Koppel, C | 1 |
| Lauwers, GY | 1 |
| Zhu, AX | 2 |
| Jain, RK | 1 |
| Duda, DG | 1 |
| Westra, IM | 1 |
| Oosterhuis, D | 1 |
| Groothuis, GM | 1 |
| Olinga, P | 1 |
| Inghilesi, AL | 1 |
| Gallori, D | 1 |
| Antonuzzo, L | 1 |
| Forte, P | 1 |
| Tomcikova, D | 1 |
| Arena, U | 1 |
| Colagrande, S | 1 |
| Pradella, S | 1 |
| Fani, B | 1 |
| Gianni, E | 1 |
| Boni, L | 1 |
| Laffi, G | 1 |
| Di Costanzo, F | 1 |
| Marra, F | 1 |
| Kikuchi, L | 1 |
| Oliveira, CP | 2 |
| Alvares-da-Silva, MR | 1 |
| Tani, CM | 1 |
| Diniz, MA | 1 |
| Stefano, JT | 2 |
| Chagas, AL | 1 |
| Alencar, RS | 1 |
| Vezozzo, DC | 1 |
| Santos, GR | 1 |
| Campos, PB | 1 |
| Alves, VA | 1 |
| Ratziu, V | 1 |
| Carrilho, FJ | 2 |
| Albines, GS | 1 |
| Mesa, A | 1 |
| Fuentes-Martínez, N | 1 |
| Pérez, R | 1 |
| Fernández-Molina, J | 1 |
| Rodríguez, M | 2 |
| Varela, M | 3 |
| Romero Gutiérrez, M | 2 |
| Ruano Díaz, L | 1 |
| Muñoz López, D | 1 |
| Artaza Varasa, T | 1 |
| González de Frutos, C | 2 |
| Sánchez Ruano, JJ | 1 |
| de la Cruz Pérez, G | 2 |
| Gómez Rodríguez, R | 2 |
| de León, FJ | 1 |
| Blanes, MM | 1 |
| Albares, MP | 1 |
| Berbegal, L | 1 |
| Pereira, IV | 1 |
| Torres, MM | 1 |
| Bida, PM | 1 |
| Coelho, AM | 1 |
| Xerfan, MP | 1 |
| Cogliati, B | 1 |
| Barbeiro, DF | 1 |
| Mazo, DF | 1 |
| Kubrusly, MS | 1 |
| D'Albuquerque, LA | 1 |
| Souza, HP | 1 |
| Ogino, YU | 1 |
| Higai, K | 1 |
| Su, TH | 1 |
| Shiau, CW | 1 |
| Jao, P | 1 |
| Liu, CJ | 1 |
| Tai, WT | 1 |
| Jeng, YM | 1 |
| Yang, HC | 1 |
| Tseng, TC | 1 |
| Huang, HP | 1 |
| Cheng, HR | 1 |
| Chen, PJ | 1 |
| Chen, KF | 1 |
| Kao, JH | 1 |
| Chen, DS | 1 |
| Lin, TsT | 1 |
| Gao, DY | 1 |
| Liu, YC | 1 |
| Sung, YC | 1 |
| Wan, D | 1 |
| Liu, JY | 1 |
| Chiang, T | 1 |
| Liu, C | 1 |
| Yang, Z | 1 |
| Lu, Y | 1 |
| Tang, B | 1 |
| Miao, H | 1 |
| Xu, Q | 1 |
| Chen, X | 1 |
| Elleuch, N | 1 |
| Ennaifer, R | 1 |
| Romdhane, H | 1 |
| Cheikh, M | 1 |
| Hefaiedh, R | 1 |
| Bougassas, W | 1 |
| Ben Nejma, H | 1 |
| BelHadj, N | 1 |
| Itokawa, N | 1 |
| Atsukawa, M | 1 |
| Tsubota, A | 1 |
| Okubo, T | 1 |
| Arai, T | 1 |
| Nakagawa, A | 1 |
| Kondo, C | 1 |
| Iwakiri, K | 1 |
| Hiensch, R | 1 |
| Meinhof, K | 1 |
| Nandedkar, D | 1 |
| Chun, G | 1 |
| Dua, S | 1 |
| Sanoff, HK | 1 |
| Chang, Y | 1 |
| Lund, JL | 1 |
| O'Neil, BH | 1 |
| Dusetzina, SB | 1 |
| Parikh, ND | 1 |
| Marshall, VD | 1 |
| Singal, AG | 1 |
| Nathan, H | 1 |
| Lok, AS | 1 |
| Balkrishnan, R | 1 |
| Shahinian, V | 1 |
| Ma, R | 1 |
| Chen, J | 1 |
| Liang, Y | 1 |
| Lin, S | 1 |
| Zhu, L | 1 |
| Liang, X | 1 |
| Cai, X | 1 |
| Llanos, L | 1 |
| Bellot, P | 1 |
| Zapater, P | 1 |
| Pérez-Mateo, M | 1 |
| Such, J | 1 |
| Yau, T | 2 |
| Chan, P | 2 |
| Ng, KK | 1 |
| Chok, SH | 1 |
| Cheung, TT | 2 |
| Fan, ST | 2 |
| Poon, RT | 1 |
| Mejias, M | 1 |
| Garcia-Pras, E | 1 |
| Tiani, C | 1 |
| Miquel, R | 1 |
| Bosch, J | 1 |
| Fernandez, M | 1 |
| Pinter, M | 2 |
| Sieghart, W | 2 |
| Graziadei, I | 1 |
| Maieron, A | 1 |
| Königsberg, R | 1 |
| Weissmann, A | 1 |
| Kornek, G | 1 |
| Plank, C | 1 |
| Peck-Radosavljevic, M | 3 |
| Clark, JW | 1 |
| Gogia, S | 1 |
| Befeler, AS | 1 |
| Shah, VH | 1 |
| Bruix, J | 3 |
| Meza-Junco, J | 1 |
| Chu, QS | 1 |
| Christensen, O | 1 |
| Rajagopalan, P | 1 |
| Das, S | 1 |
| Stefanyschyn, R | 1 |
| Sawyer, MB | 1 |
| Cabrera, R | 1 |
| Nelson, DR | 1 |
| Greten, TF | 1 |
| Lammer, J | 1 |
| Rosmorduc, O | 1 |
| Sangro, B | 1 |
| Santoro, A | 1 |
| Bolondi, L | 1 |
| Saif, MW | 1 |
| Reig, M | 2 |
| de la Mata, M | 2 |
| Matilla, A | 2 |
| Bustamante, J | 2 |
| Pascual, S | 1 |
| Turnes, J | 1 |
| Aracil, C | 1 |
| Del Val, A | 1 |
| Pascasio, JM | 1 |
| Ozenne, V | 1 |
| Paradis, V | 1 |
| Pernot, S | 1 |
| Castelnau, C | 1 |
| Vullierme, MP | 1 |
| Bouattour, M | 1 |
| Valla, D | 1 |
| Farges, O | 1 |
| Degos, F | 1 |
| Wang, SX | 1 |
| Byrnes, A | 1 |
| Verma, S | 1 |
| Pancoast, JR | 1 |
| Rixe, O | 1 |
| Vagefi, PA | 1 |
| Hirose, R | 1 |
| Wang, Y | 1 |
| Gao, J | 1 |
| Zhang, D | 1 |
| Zhang, J | 1 |
| Ma, J | 1 |
| Jiang, H | 1 |
| Varela-Rey, M | 1 |
| Martínez-López, N | 1 |
| Fernández-Ramos, D | 1 |
| Embade, N | 1 |
| Calvisi, DF | 1 |
| Woodhoo, A | 1 |
| Rodríguez, J | 1 |
| Fraga, MF | 1 |
| Julve, J | 1 |
| Rodríguez-Millán, E | 1 |
| Frades, I | 1 |
| Torres, L | 1 |
| Luka, Z | 1 |
| Wagner, C | 1 |
| Esteller, M | 1 |
| Lu, SC | 1 |
| Martínez-Chantar, ML | 1 |
| Mato, JM | 1 |
| Castells, L | 1 |
| Delgado, M | 1 |
| Moreno, JM | 1 |
| Forner, A | 2 |
| Sacco, R | 2 |
| Bargellini, I | 1 |
| Gianluigi, G | 1 |
| Bertini, M | 1 |
| Bozzi, E | 1 |
| Altomare, E | 1 |
| Battaglia, V | 1 |
| Romano, A | 1 |
| Bertoni, M | 1 |
| Capria, A | 1 |
| Bresci, G | 1 |
| Bartolozzi, C | 1 |
| Schütte, K | 1 |
| Zimmermann, L | 1 |
| Bornschein, J | 1 |
| Csepregi, A | 1 |
| Rühl, R | 1 |
| Ricke, J | 1 |
| Malfertheiner, P | 1 |
| Coriat, R | 1 |
| Gouya, H | 1 |
| Mir, O | 1 |
| Ropert, S | 1 |
| Vignaux, O | 1 |
| Chaussade, S | 1 |
| Sogni, P | 1 |
| Pol, S | 1 |
| Blanchet, B | 1 |
| Legmann, P | 1 |
| Goldwasser, F | 1 |
| Jin, J | 1 |
| Lee, KB | 1 |
| Park, SY | 1 |
| Jang, JJ | 1 |
| Thabut, D | 1 |
| Routray, C | 1 |
| Lomberk, G | 1 |
| Shergill, U | 1 |
| Glaser, K | 1 |
| Huebert, R | 1 |
| Patel, L | 1 |
| Masyuk, T | 1 |
| Blechacz, B | 1 |
| Vercnocke, A | 1 |
| Ritman, E | 1 |
| Ehman, R | 1 |
| Urrutia, R | 1 |
| Shah, V | 1 |
| Abou-Alfa, GK | 1 |
| Chan, SL | 1 |
| Lin, CC | 1 |
| Chiorean, EG | 1 |
| Holcombe, RF | 1 |
| Mulcahy, MF | 1 |
| Carter, WD | 1 |
| Patel, K | 1 |
| Wilson, WR | 1 |
| Melink, TJ | 1 |
| Gutheil, JC | 1 |
| Tsao, CJ | 1 |
| De Ruvo, N | 1 |
| D'Amico, G | 1 |
| Iemmolo, RM | 1 |
| Gerunda, GE | 1 |
| de Artaza Varasa, T | 1 |
| Ciampi Dopazo, JJ | 1 |
| Lanciego Pérez, C | 1 |
| Gómez Moreno, AZ | 1 |
| Rohr-Udilova, N | 1 |
| Ferlitsch, A | 1 |
| Mínguez, B | 1 |
| Lachenmayer, A | 1 |
| Cabibbo, G | 1 |
| Rolle, E | 1 |
| De Giorgio, M | 1 |
| Genco, C | 1 |
| Pressiani, T | 1 |
| Spada, F | 1 |
| Kudo, M | 1 |
| Sansonno, D | 1 |
| Lauletta, G | 1 |
| Russi, S | 1 |
| Conteduca, V | 1 |
| Sansonno, L | 1 |
| Dammacco, F | 1 |
| Llovet, JM | 1 |
| Nguyen, V | 1 |
| George, J | 1 |
| van der Poorten, D | 1 |
| Xie, B | 1 |
| Wang, DH | 1 |
| Spechler, SJ | 1 |
| Kurniali, PC | 1 |
| O'Gara, K | 1 |
| Wang, X | 1 |
| Wang, LJ | 1 |
| Somasundar, P | 1 |
| Falanga, V | 1 |
| Espat, NJ | 1 |
| Katz, SC | 1 |
| Chiu, J | 1 |
| Tang, YF | 1 |
| Yao, TJ | 1 |
| Wong, A | 1 |
| Wong, H | 1 |
| Leung, R | 1 |
| Chan, AC | 1 |
| Pang, R | 1 |
| Poon, R | 1 |
| Iida, K | 1 |
| Hong, F | 1 |
| Chou, H | 1 |
| Fiel, MI | 1 |
| Friedman, SL | 1 |
| Koschny, R | 1 |
| Gotthardt, D | 1 |
| Koehler, C | 1 |
| Jaeger, D | 1 |
| Stremmel, W | 1 |
| Ganten, TM | 1 |
| Di Costanzo, GG | 1 |
| Tortora, R | 1 |
| De Luca, M | 1 |
| Galeota Lanza, A | 1 |
| Lampasi, F | 1 |
| Tartaglione, MT | 1 |
| Picciotto, FP | 1 |
| Imparato, M | 1 |
| Mattera, S | 1 |
| Cordone, G | 1 |
| Ascione, A | 1 |
| Gabuzda, GJ | 1 |
| Davidson, CS | 1 |
| CAMATTE, R | 1 |
| BENVESTITO, V | 1 |
| MARTELLOTTA, G | 1 |
| VIGGIANO, N | 1 |
| Traister, A | 1 |
| Breitman, I | 1 |
| Bar-Lev, E | 1 |
| Zvibel, I | 1 |
| Harel, A | 1 |
| Halpern, Z | 1 |
| Oren, R | 1 |
| Cuomo, R | 2 |
| Dattilo, M | 1 |
| Pumpo, R | 2 |
| Capuano, G | 1 |
| Boselli, L | 1 |
| Budillon, G | 2 |
| Orlando, R | 1 |
| Floreani, M | 1 |
| Napoli, E | 1 |
| Padrini, R | 1 |
| Palatini, P | 1 |
| Sarnelli, G | 1 |
| Spinella, A | 1 |
| Akhundzhanov, BA | 2 |
| Morgan, AG | 1 |
| Kelleher, J | 1 |
| Walker, BE | 1 |
| Losowsky, MS | 1 |
| Somogyi, A | 1 |
| Siebert, D | 1 |
| Bochner, F | 1 |
| Pagliaro, L | 1 |
| Catalfamo, G | 1 |
| Melotti, G | 1 |
| Soffritti, E | 1 |
| Corridsen, V | 1 |
| Passerini, A | 1 |
| Polito, C | 1 |
| Lancia, M | 1 |
| Chiancone, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486] | Phase 2 | 160 participants (Actual) | Interventional | 2011-11-14 | Completed | ||
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial[NCT00717756] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.[NCT00692770] | Phase 3 | 1,114 participants (Actual) | Interventional | 2008-08-15 | Completed | ||
| Prospective Evaluation of Tumor Response to Cancer Treatment Therapies[NCT02787954] | 10 participants (Actual) | Observational [Patient Registry] | 2016-01-31 | Terminated (stopped due to PI transferred to another institution and did not take this study with him.) | |||
| Clinical Study of Transarterial Chemoembolization (TACE) Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma[NCT02630108] | Phase 3 | 280 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| A Single-arm, Non-randomized, Single-center Study to Evaluate Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma[NCT04443309] | Phase 1/Phase 2 | 53 participants (Anticipated) | Interventional | 2020-09-11 | Recruiting | ||
| Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma: a Single-center, Single-arm, Non-randomized Clinical Study[NCT04368078] | Phase 2 | 76 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| Stereotactic Image-Guided Microwave Ablation for Hepatocellular Carcinoma - Does Computer-assistance Broaden Eligibility and Efficacy of Ablative Treatment?[NCT03630068] | 87 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| Radiofrequency Ablation or Surgical Resection Combined With Neo-MASCT for Primary Hepatocellular Carcinoma: a Randomised, Multicentre Phase II Trial[NCT03067493] | Phase 2 | 98 participants (Anticipated) | Interventional | 2017-07-25 | Recruiting | ||
| DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab[NCT04954339] | Phase 2 | 45 participants (Anticipated) | Interventional | 2021-10-29 | Recruiting | ||
| Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.[NCT05166239] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD~It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed." (NCT00717756)
Timeframe: on average about every 2 months until progression, on average about 4 months.
| Intervention | participants (Number) |
|---|---|
| Lenalidomide | 6 |
"OS was defined as the time from randomization to date of death due to any cause. OS for subjects alive at the time of analysis was censored at their last date of contact. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization of the first subject until 4 years later.
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | NA |
| Placebo | NA |
The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D Index is a descriptive system of the following health dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Subjects were asked to choose any one of the 3 response levels for each dimension: no problems, some problems, and severe problems. The 5 health dimensions were summarized into a single score, the EQ-5D Index score which ranged from -0.59 to 1 with higher scores representing better health states (0=death, 1= perfect health, and -0.59=a health state worse than death). A change of at least 0.10 to 0.12 points was considered a minimally important difference using Eastern Cooperative Oncology Group Performance Status as the anchor. The results on the Analysis of covariance of timeadjusted Area under curve for the EQ-5D index score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.827 |
| Placebo | 0.866 |
The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D VAS is a measure that represents health status as a single value. It is a 20-centimetre vertical graduated visual analogue scale with scores that ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). The respondent rated his/her current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the EQ-5D VAS. A 3-digit number (including leading zeros) was read off the scale from the point where the respondent's line crossed the scale, which was the EQ-5D VAS score. A change of at least 7 points on the VAS was considered as minimally important. The results on the ANCOVA analysis of time-adjusted AUC for the EQ-5D VAS score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 77.203 |
| Placebo | 80.181 |
The PWB, FWB, SWB and EWB were summed to form the FACT-G total score. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). FACT-G scores ranged from 0 to 108 and the higher scores represented a better quality of life. The MID for the FACT-G total score was in the range of 6 to 7. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-G score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 80.46 |
| Placebo | 82.95 |
The FACT-HEP is a 45 item, self-administered, multi-dimensional, psychometrically sound questionnaire used extensively in oncology clinical trials. FACT-HEP consisted of five subscales: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The PWB, FWB, SWB and EWB were summed to form the FACTGeneral (FACT-G) total score. The FACT-G and HCS scores were summed to form the FACT-HEP total score. FACT-HEP scores ranged from 0 to 180 and the higher scores represented a better quality of life. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). The minimally important difference (MID) for the FACT-Hep total score was in the range of 8 to 9. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-HEP score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 138.7 |
| Placebo | 143.79 |
Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans. RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death. (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 1014 |
| Placebo | 1026 |
"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline
| Intervention | Days (Median) |
|---|---|
| AFP High Expression Group | 668 |
| AFP Low Expression Group | 1267 |
"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline
| Intervention | Days (Median) |
|---|---|
| ANG-2 High Expression Group | 588 |
| ANG-2 Low Expression Group | 1260 |
"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline
| Intervention | Days (Median) |
|---|---|
| MET High Expression Group | 841 |
| MET Low Expression Group | NA |
"TTR was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment. For subjects who had not recurred at the time of analysis, TTR was censored at their last date of evaluable scan before withdrawal for any other reason than recurrence. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 1172 |
| Placebo | 1089 |
9 reviews available for niacinamide and Liver Cirrhosis
| Article | Year |
|---|---|
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm | 2017 |
Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
Topics: Animals; Cellular Microenvironment; Humans; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compound | 2017 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C | 2010 |
Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; D | 2011 |
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Management; Humans; Liv | 2011 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, | 2011 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2012 |
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoemb | 2012 |
6 trials available for niacinamide and Liver Cirrhosis
| Article | Year |
|---|---|
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver | 2021 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Fema | 2009 |
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progressio | 2011 |
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Be | 2011 |
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progress | 2012 |
81 other studies available for niacinamide and Liver Cirrhosis
| Article | Year |
|---|---|
Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment.
Topics: Aged; Antiviral Agents; Biomarkers; Hepatitis C; Humans; Hydroxybutyrates; Liver Cirrhosis; Male; Me | 2021 |
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinam | 2023 |
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liv | 2022 |
Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
Topics: Animals; Fingolimod Hydrochloride; Hepatopulmonary Syndrome; Inflammation; Liver Cirrhosis; Mice; Ni | 2023 |
Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinam | 2020 |
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; France; | 2017 |
Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, | 2018 |
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-45 | 2018 |
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fl | 2018 |
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2018 |
NNMT activation can contribute to the development of fatty liver disease by modulating the NAD
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fatty Liver; Lipoproteins, VLDL; Liver | 2018 |
Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice.
Topics: Actins; Animals; Collagen Type I; Collagen Type III; Female; Liver; Liver Cirrhosis; Mice; Mice, Inb | 2018 |
Alleviation of fatty liver in a rat model by enhancing N
Topics: Aldehyde Oxidase; Animals; Biological Availability; Cytosol; Disease Models, Animal; Enzyme Inhibito | 2018 |
Nicotinamide riboside protects against liver fibrosis induced by CCl
Topics: Acetylation; Animals; Carbon Tetrachloride; E1A-Associated p300 Protein; Gene Expression Regulation; | 2019 |
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
Topics: Aged; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Cognition Disorders; Electroencephalogra | 2013 |
Liver tumors and loco-regional therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2013 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; | 2013 |
STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Topics: Actins; Active Transport, Cell Nucleus; Animals; Carbon Tetrachloride; Cell Nucleus; Cells, Cultured | 2013 |
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Fem | 2014 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Move | 2014 |
Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.
Topics: Animals; Becaplermin; Benzamides; Benzylisoquinolines; Cinnamates; Collagen Type I; Connective Tissu | 2014 |
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distrib | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, H | 2016 |
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; He | 2015 |
[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice].
Topics: Aged; Aged, 80 and over; Alcoholism; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization | 2015 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethan | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collag | 2015 |
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Ci | 2015 |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
Topics: Animals; Cell Line; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C | 2015 |
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Topics: Animals; Carbon Tetrachloride; Drug Carriers; Human Umbilical Vein Endothelial Cells; Lactic Acid; L | 2016 |
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.
Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Cytokines; Dimethylnitrosamine; Drug Therapy | 2015 |
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver | 2015 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2016 |
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Dyspnea; Em | 2016 |
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; | 2016 |
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Databases, Factual; F | 2017 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical a | 2009 |
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Topics: Animals; Benzenesulfonates; Collateral Circulation; Enteritis; Heme Oxygenase-1; Hepatitis; Hyperten | 2009 |
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2009 |
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver | 2009 |
Treating hepatocellular carcinoma without liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cathet | 2009 |
Antiangiogenic therapy: not just for cancer anymore?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension, Po | 2009 |
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinic | 2009 |
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; | 2010 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver | 2010 |
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2010 |
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cir | 2010 |
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis | 2010 |
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Topics: Animals; Apoptosis; Base Sequence; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cel | 2010 |
Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide.
Topics: Animals; Fatty Liver; Gene Deletion; Gene Expression; Glycine N-Methyltransferase; Liver Cirrhosis; | 2010 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovas | 2010 |
Complete response for advanced liver cancer during sorafenib therapy: case report.
Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatoce | 2011 |
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hep | 2011 |
Nicotinamide inhibits hepatic fibrosis by suppressing DNA synthesis and enhancing apoptosis of hepatic stellate cells.
Topics: Actins; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cells, Cultured; Collagen; Disease Model | 2011 |
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.
Topics: Animals; Benzenesulfonates; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Hepatic Stell | 2011 |
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therap | 2012 |
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Earl | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirr | 2012 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular | 2012 |
The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationshi | 2012 |
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2012 |
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell C | 2012 |
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepatic Stel | 2013 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up S | 2013 |
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Femal | 2013 |
Tryptophan and nicotinic acid metabolism in patients with cirrhosis of the liver.
Topics: Liver Cirrhosis; Niacin; Niacinamide; Nicotinic Acids; Tryptophan | 1962 |
[Therapeutic trials of "Benutrex" in viral hepatitis and cirrhosis].
Topics: Hepatitis; Hepatitis A; Humans; Liver Cirrhosis; Liver Extracts; Niacin; Niacinamide; Pantothenic Ac | 1962 |
[CLINICO-EXPERIMENTAL STUDY OF A NEW CHOLERETIC ASSOCIATED WITH AN ANTI-SPASTIC DRUG AND WITH VITAMIN B1 AND VITAMIN PP].
Topics: Cholagogues and Choleretics; Cholecystitis; Cholelithiasis; Hepatitis; Jaundice; Liver Cirrhosis; Mu | 1963 |
Nicotinamide induces apoptosis and reduces collagen I and pro-inflammatory cytokines expression in rat hepatic stellate cells.
Topics: Actins; Animals; Apoptosis; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Cycle; | 2005 |
Nicotinamide methylation in patients with cirrhosis.
Topics: Female; Humans; Liver; Liver Cirrhosis; Male; Methylation; Methyltransferases; Middle Aged; Niacinam | 1994 |
Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis.
Topics: Adult; Biological Transport, Active; Biomarkers; Case-Control Studies; Creatinine; Humans; Inulin; K | 2000 |
The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production.
Topics: Adult; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Niacinamide | 2001 |
[Surgical treatment of liver cirrhosis with the use of regeneration stimulators].
Topics: Adult; Animals; Dogs; Female; gamma-Globulins; Hepatectomy; Humans; Liver Cirrhosis; Liver Regenerat | 1976 |
[Remote results of surgical treatment of liver cirrhosis with the use of regeneration stimulants].
Topics: Adolescent; Cobalt; Follow-Up Studies; gamma-Globulins; Humans; Liver Cirrhosis; Liver Regeneration; | 1978 |
Nutrition in cryptogenic cirrhosis and chronic aggressive hepatitis.
Topics: Adult; Aged; Ascorbic Acid Deficiency; Carotenoids; Eating; Folic Acid Deficiency; Hepatitis; Humans | 1976 |
Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by high-performance liquid chromatography.
Topics: Acetophenones; Adolescent; Adult; Aged; Aging; Chromatography, High Pressure Liquid; Female; Fluores | 1990 |
[Treatment of patients with chronic liver diseases with a hepatotrophic preparation].
Topics: Bilirubin; Cholinesterases; Chronic Disease; Folic Acid; gamma-Globulins; Hepatitis; Humans; Liver C | 1971 |
[Clinico-experimental findings on the use of a new liver protective agent].
Topics: Adult; Aged; Arginine; Citrulline; Female; Folic Acid; Hepatitis; Humans; Liver Cirrhosis; Male; Mid | 1967 |
[A case of liver cirrhosis treated with pyridine-3-carboxylic acid hydroxymethylamide (Bilamid)].
Topics: Aged; Female; Humans; Liver Cirrhosis; Niacinamide | 1967 |
[Clinical observations on the use of an amino-acid and vitamin compound in acute and chronic hepatopathies].
Topics: Aged; Amino Acids; Female; Folic Acid; Hepatitis A; Humans; Liver Cirrhosis; Male; Middle Aged; Niac | 1968 |
[Social aspects and new therapeutic trends in Italian vitamin research during the last 30 years].
Topics: Child Health Services; Hepatitis; Humans; Italy; Liver Cirrhosis; Niacinamide; Nicotinic Acids; Orot | 1971 |